Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
The effects of GLP-1RAs on colorectal and other cancer risk Clinical studies have demonstrated that the use of GLP-1RAs can reduce the risk of colorectal cancer, and the protective effect appears to be positively correlated with the duration of therapy
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity owenhaskins Aug 28, 2024 3 min read Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand
Clinicians: the GLP-1 Bridge prior authorization form, explained
Key Features: Prescription-strength formula
doi: 10.1111/dom.15802
Live synchronous video consults
US$ 28.02
US$ 21.30
US$ 20.58
US$ 24.55
